First Patient Outside US Treated in Trial for Severe COVID-19 Patients

This scanning electron microscope image shows the SARS-CoV-2 virus (round yellowish objects), which The Epoch Times refers to as the CCP virus, emerging from the surface of cells cultured in the lab. Photo published Feb. 19, 2020. NIAID-RML

The first patient outside the United States was treated in a trial analyzing an antibody that inhibits the interleukin-6 (IL-6) pathway on patients with severe COVID-19.

The new illness is caused by the CCP (Communist Chinese Party) virus.